Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.68 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.68 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | PIM1 | P11309 | 1/20 | 0.68 |
| ▸ | PRKACA | P17612 | 1/20 | 0.68 |
| ▸ | LTK | P29376 | 1/20 | 0.68 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.68 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.68 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.68 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.68 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.68 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.68 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.68 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.68 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29690398 | 1.00 | EGFR (1.00) | EGFRERBB2MAPK1KDM4EHTT | |
| SCHEMBL2103341 | 0.90 | EGFR (0.82) | EGFRERBB2KDM4ELMNA | |
| SCHEMBL15051638 | 0.88 | EGFR (0.78) | EGFRERBB2MAPK1KDM4EHTT | |
| SCHEMBL7234980 | 0.87 | EGFR (0.77) | EGFRERBB2MAPK1KDM4EHTT | |
| SCHEMBL18996629 | 0.87 | EGFR (1.00) | EGFRERBB2MAPK1KDM4EHTT | |
| Hydrochloric Acid SCHEMBL7240600 | 0.86 | EGFR (0.75) | EGFRERBB2MAPK1KDM4EHTT | |
| SCHEMBL4586685 | 0.86 | EGFR (0.75) | EGFRERBB2KDM4ELMNA | |
| SCHEMBL2987637 | 0.85 | EGFR (0.73) | EGFRERBB2MAPK1KDM4EHTT | |
| SCHEMBL27685863 | 0.84 | EGFR (0.73) | EGFRERBB2MAPK1KDM4EHTT | |
| SCHEMBL27923391 | 0.84 | EGFR (0.73) | EGFRERBB2CLK4RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411993-B1 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RES DEV CO (IL) | 2010-05-05 | — | — | EP | claimed |
| EP-1594504-A4 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T K SIGNAL LTD (IL) | 2008-12-17 | — | — | EP | claimed |
| EP-1411993-A4 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RES DEV CO (IL) | 2007-08-01 | — | — | EP | claimed |
| US-7172749-B2 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-02-06 | — | — | US | claimed |
| EP-1673110-A2 | RADIOLABELED ANILINOQUINAZOLINES AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-06-28 | — | — | EP | claimed |
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | T.K. SIGNAL LTD. (IL) | 2006-02-02 | — | — | US | claimed |
| EP-1594504-A2 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T.K. Signal Ltd. (IL) | 2005-11-16 | — | — | EP | claimed |
| WO-2005023315-A2 | RADIOLABELED ANILINOQUINAZOLINES AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-03-17 | — | — | WO | claimed |
| US-20040265228-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2004-12-30 | — | — | US | claimed |
| WO-2004064718-A2 | IRREVERSIBLE INHIBITORS OF EGF RECEPTOR TYROSINE KINASES AND USES THEREOF | T.K. SIGNAL LTD. (IL) | 2004-08-05 | — | — | WO | claimed |
| EP-1411993-A2 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-04-28 | — | — | EP | claimed |
| US-6562319-B2 | 4-(phenylamino)quinazolines | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-05-13 | — | — | US | claimed |
| WO-2002073235-A2 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-09-19 | — | — | WO | claimed |
| US-20020128553-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. | 2002-09-12 | — | — | US | claimed |
| CN-109942500-B | Preparation of rhein anilino quinazoline derivatives and anti-tumor application | 广西医科大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-105753793-B | Fragrant formyl urea coupling quinazoline compounds and preparation method thereof, pharmaceutical composition and medicinal usage | 河北医科大学 | 2018-09-04 | — | — | CN | disclosed |
| WO-2017008757-A1 | 1-SUBSTITUTED PHENYL-3-(4-SUBSTITUTED PHENYLAMINO-6-QUINAZOLINYL)UREA COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | 西安交通大学 | 2017-01-19 | — | — | WO | disclosed |
| US-5760041-A | 4-aminoquinazoline EGFR Inhibitors | AMERICAN CYANAMID COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| CN-1161330-A | Substd. quinazoline derivatives | AMERICAN CYANAMID CO (US) | 1997-10-08 | — | — | CN | disclosed |
| EP-0787722-A1 | Substituted quinazoline derivatives | American Cyanamid Company (US) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128553-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | EGFR, ERBB2, TK1 | EGFR 1/4885ERBB2 2/4885MAPK1 587/4885 |
| US-20040265228-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | EGFR, ERBB2, TK1 | EGFR 1/4885ERBB2 2/4885MAPK1 587/4885 |
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885MAPK1 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.